CL2018000293A1 - Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa - Google Patents
Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfaInfo
- Publication number
- CL2018000293A1 CL2018000293A1 CL2018000293A CL2018000293A CL2018000293A1 CL 2018000293 A1 CL2018000293 A1 CL 2018000293A1 CL 2018000293 A CL2018000293 A CL 2018000293A CL 2018000293 A CL2018000293 A CL 2018000293A CL 2018000293 A1 CL2018000293 A1 CL 2018000293A1
- Authority
- CL
- Chile
- Prior art keywords
- modulators
- tnf
- alpha
- necrosis factor
- tumor necrosis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>SE DESCRIBEN LOS COMPUESTOS DE LA FÓRMULA (I) O UNA SAL DEL MISMO, EN DONDE: A ES CR1 O N; B ES CR3 O N; D ES CR4 O N; L1 ES -(CR7R7)M-; L2 ES -(CR7R7)N-; Y X, Z, R1, R2, R3, R4, R5 Y R6 SE DEFINEN EN LA PRESENTE. TAMBIÉN SE DESCRIBEN MÉTODOS PARA USAR TALES COMPUESTOS COMO MODULADORES DE TNFA, Y COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS. ESTOS COMPUESTOS SON ÚTILES PARA TRATAR ENFERMEDADES INFLAMATORIAS Y AUTOINMUNITARIAS.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562200424P | 2015-08-03 | 2015-08-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2018000293A1 true CL2018000293A1 (es) | 2018-07-13 |
Family
ID=56618285
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2018000293A CL2018000293A1 (es) | 2015-08-03 | 2018-02-01 | Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa |
Country Status (22)
Country | Link |
---|---|
US (1) | US10865191B2 (es) |
EP (1) | EP3331871A1 (es) |
JP (1) | JP6955482B2 (es) |
KR (1) | KR20180031772A (es) |
CN (1) | CN108137547B (es) |
AR (1) | AR105575A1 (es) |
AU (1) | AU2016302144B2 (es) |
BR (1) | BR112018001960A2 (es) |
CA (1) | CA2994717A1 (es) |
CL (1) | CL2018000293A1 (es) |
CO (1) | CO2018002061A2 (es) |
EA (1) | EA033686B1 (es) |
HK (1) | HK1252623A1 (es) |
IL (1) | IL257154A (es) |
MA (1) | MA43512A (es) |
MX (1) | MX2018001054A (es) |
PE (1) | PE20181366A1 (es) |
SG (1) | SG10201911831RA (es) |
TW (1) | TW201718536A (es) |
UY (1) | UY36838A (es) |
WO (1) | WO2017023905A1 (es) |
ZA (1) | ZA201800716B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016168633A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
AR104291A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Moduladores tricíclicos de la señalización por tnf |
WO2016168638A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Indazolones as modulators of tnf signaling |
GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
CA2993304C (en) | 2015-08-03 | 2021-06-22 | Glenmark Pharmaceuticals S.A. | Novel compounds as ror gamma modulators |
GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
JOP20190257A1 (ar) | 2017-04-28 | 2019-10-28 | Novartis Ag | مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats |
CA3090788A1 (en) * | 2018-02-09 | 2019-08-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Heterocyclic p2y14 receptor antagonists |
CN108658977A (zh) * | 2018-04-12 | 2018-10-16 | 苏州康润医药有限公司 | 一种7-溴-1,5-萘啶-3-甲酸的合成方法 |
EP4153566A1 (en) | 2020-05-19 | 2023-03-29 | Bayer CropScience Aktiengesellschaft | Azabicyclic(thio)amides as fungicidal compounds |
CA3186659A1 (en) | 2020-06-10 | 2021-12-16 | Bayer Aktiengesellschaft | Azabicyclyl-substituted heterocycles as fungicides |
US11926632B2 (en) | 2020-06-22 | 2024-03-12 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
EP4267554A1 (en) * | 2020-12-22 | 2023-11-01 | Mekanistic Therapeutics LLC | Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors |
WO2023067546A1 (en) * | 2021-10-21 | 2023-04-27 | Satyarx Pharma Innovations Pvt Ltd | Novel bicyclic heteroaryl derivatives as sos1:kras proteinprotein interaction inhibitors |
CN114605409B (zh) * | 2022-04-01 | 2024-04-02 | 苏州睿尔思科技有限公司 | 一种4-羟基-1,5-萘啶类配体的生产制备方法 |
CN114751858B (zh) * | 2022-04-20 | 2023-09-12 | 沈阳药科大学 | 含有喹啉基的氨甲环酸衍生物及其制备与应用 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US856095A (en) * | 1906-09-01 | 1907-06-04 | Railway Safety Signal Company | Electric semaphore. |
FI91401C (fi) * | 1987-03-17 | 1994-06-27 | Hoechst Roussel Pharma | Menetelmä terapeuttisesti aktiivisten substituoitujen 9-aminotetrahydroakriinien ja niille läheisten yhdisteiden valmistamiseksi |
DE3917232A1 (de) * | 1989-05-26 | 1990-11-29 | Basf Ag | 4-arylmethamino-2,3-dialkyl-chinoline, ihre verwendung und daraus hergestellte arzneimittel |
BR0209719A (pt) * | 2001-05-31 | 2004-07-27 | Sanofi Synthelabo | Derivados de aminoquinolina e aminopiridina e seu uso como ligandos de adenosina a3 |
EP1427408A4 (en) * | 2001-09-17 | 2005-10-26 | Bristol Myers Squibb Co | CYCLIC HYDROXAMINE ACIDS AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-a-CONVERTASE (TACE TNF-a-CONVERTING ENZYM) |
AU2002357312A1 (en) | 2001-12-20 | 2003-07-09 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases |
HUP0105406A3 (en) * | 2001-12-21 | 2003-12-29 | Sanofi Aventis | Imidazo[1,2-a]quinolin derivatives, process for their preparation, pharmaceutical compositions thereof and intermediates |
MXPA06001254A (es) | 2003-07-31 | 2006-05-17 | Sanofi Aventis | Derivados de aminoquinolina y su uso como ligantes de adenosina a3. |
TW200815447A (en) | 2006-06-14 | 2008-04-01 | Astrazeneca Ab | Novel compounds IV |
EP2307400B1 (en) * | 2008-05-30 | 2014-04-23 | Amgen, Inc | Inhibitors of pi3 kinase |
RU2582610C2 (ru) * | 2010-07-30 | 2016-04-27 | Онкотерапи Сайенс, Инк. | Производные хинолина и содержащие их ингибиторы melk |
CN104428293B (zh) | 2012-06-11 | 2018-06-08 | Ucb生物制药私人有限公司 | 调节TNFα的苯并咪唑类 |
ES2689429T3 (es) | 2012-07-13 | 2018-11-14 | Ucb Biopharma Sprl | Derivados de imidazopiridina como moduladores de actividad de TNF |
GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
CN105102000B (zh) * | 2012-11-01 | 2021-10-22 | 无限药品公司 | 使用pi3激酶亚型调节剂的癌症疗法 |
EP2968360B1 (en) * | 2013-03-14 | 2021-01-20 | ConverGene LLC | Quinolinone derivatives for the inhibition of bromodomain-containing proteins |
CA2993304C (en) | 2015-08-03 | 2021-06-22 | Glenmark Pharmaceuticals S.A. | Novel compounds as ror gamma modulators |
GB201513742D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
AR105556A1 (es) | 2015-08-03 | 2017-10-18 | Hoffmann La Roche | Derivados de etinilo |
CN109195969B (zh) | 2016-04-01 | 2021-12-21 | Ucb生物制药私人有限公司 | 作为tnf活性调节剂的稠合五环咪唑衍生物 |
-
2016
- 2016-08-02 WO PCT/US2016/045110 patent/WO2017023905A1/en active Application Filing
- 2016-08-02 MX MX2018001054A patent/MX2018001054A/es active IP Right Grant
- 2016-08-02 UY UY0001036838A patent/UY36838A/es unknown
- 2016-08-02 TW TW105124501A patent/TW201718536A/zh unknown
- 2016-08-02 AR ARP160102357A patent/AR105575A1/es unknown
- 2016-08-02 AU AU2016302144A patent/AU2016302144B2/en not_active Ceased
- 2016-08-02 EA EA201890165A patent/EA033686B1/ru not_active IP Right Cessation
- 2016-08-02 CA CA2994717A patent/CA2994717A1/en not_active Abandoned
- 2016-08-02 US US15/887,214 patent/US10865191B2/en active Active
- 2016-08-02 JP JP2018506144A patent/JP6955482B2/ja active Active
- 2016-08-02 KR KR1020187005707A patent/KR20180031772A/ko active IP Right Grant
- 2016-08-02 BR BR112018001960A patent/BR112018001960A2/pt not_active IP Right Cessation
- 2016-08-02 PE PE2018000172A patent/PE20181366A1/es unknown
- 2016-08-02 CN CN201680057509.7A patent/CN108137547B/zh active Active
- 2016-08-02 EP EP16750343.2A patent/EP3331871A1/en not_active Withdrawn
- 2016-08-02 MA MA043512A patent/MA43512A/fr unknown
- 2016-08-02 SG SG10201911831RA patent/SG10201911831RA/en unknown
-
2018
- 2018-01-25 IL IL257154A patent/IL257154A/en unknown
- 2018-02-01 CL CL2018000293A patent/CL2018000293A1/es unknown
- 2018-02-02 ZA ZA2018/00716A patent/ZA201800716B/en unknown
- 2018-02-26 CO CONC2018/0002061A patent/CO2018002061A2/es unknown
- 2018-09-17 HK HK18111924.8A patent/HK1252623A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EA201890165A1 (ru) | 2018-07-31 |
CA2994717A1 (en) | 2017-02-09 |
MX2018001054A (es) | 2018-07-06 |
PE20181366A1 (es) | 2018-08-27 |
AU2016302144B2 (en) | 2020-10-08 |
TW201718536A (zh) | 2017-06-01 |
AU2016302144A1 (en) | 2018-03-22 |
US20180222883A1 (en) | 2018-08-09 |
EA033686B1 (ru) | 2019-11-15 |
CO2018002061A2 (es) | 2018-06-20 |
CN108137547A (zh) | 2018-06-08 |
BR112018001960A2 (pt) | 2018-09-18 |
EP3331871A1 (en) | 2018-06-13 |
WO2017023905A1 (en) | 2017-02-09 |
JP6955482B2 (ja) | 2021-10-27 |
ZA201800716B (en) | 2019-07-31 |
MA43512A (fr) | 2018-11-07 |
IL257154A (en) | 2018-03-29 |
US10865191B2 (en) | 2020-12-15 |
JP2018525379A (ja) | 2018-09-06 |
HK1252623A1 (zh) | 2019-05-31 |
SG10201911831RA (en) | 2020-02-27 |
UY36838A (es) | 2017-01-31 |
KR20180031772A (ko) | 2018-03-28 |
CN108137547B (zh) | 2021-11-12 |
AR105575A1 (es) | 2017-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2018000293A1 (es) | Compuestos heterocíclicos útiles como moduladores de factor de necrosis tumoral (tnf) alfa | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
CO2017002532A2 (es) | Indazoles sustituidos con bencilo como inhibidores de bub1 | |
PH12017501817A1 (en) | Heterocyclic compounds as lsd1 inhibitors | |
CL2019002461A1 (es) | Arn terapéutico. | |
EA201790024A1 (ru) | Модуляторы toll-подобных рецепторов для лечения вич | |
CL2017002494A1 (es) | Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
SV2016005180A (es) | Amino-heteroaril-benzamidas como inhibidores de cinasa | |
EA201890307A1 (ru) | Индазольные и азаиндазольные соединения как ингибиторы irak-4 | |
EA201690316A1 (ru) | Соединения для применения в качестве иммуномодуляторов | |
EA201690027A1 (ru) | Ингибиторы ido | |
PE20151594A1 (es) | Inhibidores de indolamina 2-3 dioxigenasa | |
EA201591599A1 (ru) | Ингибиторы ido | |
EA201690306A1 (ru) | Ингибиторы ido | |
EA201690152A1 (ru) | Ингибиторы ido | |
CL2015003512A1 (es) | Uso de dianhidrogalactitol y análogos y derivados del mismo para tratar glioma maligno recurrente o tumor cerebral secundario progresivo | |
EA201590881A1 (ru) | Терапевтические соединения и композиции и их использование в качестве модуляторов пк-m2 | |
EA201890331A1 (ru) | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена | |
UY36708A (es) | MODULADORES DE ROR GAMMA (RORy) | |
DOP2016000336A (es) | Derivados de isoindolina para uso en el tratamiento de una infeccion viral | |
CL2017000152A1 (es) | Derivados de isoindolinona | |
EA201791807A1 (ru) | Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич |